UK authorizes orforglipron for weight management and type 2 diabetes, first in Europe

The UK Medicines and Healthcare products Regulatory Agency licensed orforglipron (Foundayo) on August 10, 2026, for weight management and for type 2 diabetes, making Britain the first country in Europe to clear the once-daily GLP-1 tablet ^[1]. The authorization was granted to Eli Lilly ^[1].

The weight-management license applies to adults with a BMI of 30 or higher, and to adults with a BMI between 27 and 30 who also have at least one weight-related comorbidity. It is intended for use alongside a reduced-calorie diet and more physical activity ^[1]. A separate indication covers improving blood sugar control in patients whose type 2 diabetes is not sufficiently controlled ^[1].

Julian Beach, the agency's executive director of healthcare quality and access, said the decision followed a rigorous assessment of orforglipron's safety, quality and effectiveness, and described it as the first such authorization by a European regulator. He added that the medicine is prescription-only and that the MHRA "will keep the safety and effectiveness of orforglipron under close review" ^[1].

Dosing starts at 0.8 mg and steps up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg, with at least one month spent at each level ^[1]. The tablet is taken once a day at any time, with no restrictions on food or water ^[1]. Oral semaglutide (Rybelsus) is different in that respect, because it must be taken around a fasting window ^[2].

Orforglipron belongs to the GLP-1 receptor agonist class. Injectable members of that class, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are peptides that the gut breaks down, which is why they are normally given as shots. Orforglipron is a small molecule that survives digestion, so it can be swallowed ^[2]. Like the others, it mimics a hormone released after eating and acts on appetite centers in the brain, helping people feel full longer and eat less ^[1]. The common side effects listed are nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain ^[1].

Why it matters for patients

A license is not the same as coverage. The tablet is not currently available through the NHS, and decisions on public funding follow a separate process that includes an evaluation by the National Institute for Health and Care Excellence ^[1]. Lilly began supplying the UK on August 24 through private prescription only, and has indicated private pricing of £100 to £120 per month ^[2].

In the UK the drug is prescription-only, meaning it can only come from a registered pharmacy with a doctor's prescription, and the MHRA warns that buying GLP-1 medicines from unregulated sellers carries serious health risks ^[1].

The US picture is separate. The Food and Drug Administration approved orforglipron for obesity in April 2026, and Lilly filed for type 2 diabetes in the US during the second quarter of 2026 ^[2]. No decision date for that diabetes submission has been disclosed ^[2].

The BMI thresholds in the UK authorization are set by UK regulators; other countries apply their own. The MHRA announcement does not include head-to-head results comparing orforglipron with semaglutide or tirzepatide, and no such comparison has been reported.

What happens next

• The Summary of Product Characteristics and Patient Information Leaflet are to be published on the MHRA Products website within seven days of approval ^[1].
• NICE's appraisal of orforglipron remains open. NICE asked Lilly for further information after its first committee meeting and has not scheduled a second review; the listing shows an expected publication date of November 18, 2026 ^[2].
• The FDA is reviewing Lilly's application for orforglipron in type 2 diabetes, with no action date made public ^[2].
• Suspected side effects in the UK can be reported to the MHRA Yellow Card scheme online or through its app ^[1].